News & Updates
The latest developments in peptide research, regulation, clinical trials, and market trends. Updated daily by the Volta Peptides editorial team.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
What's Next for GLP-1 Weight Loss Drugs: Industry Analysis and Peptide Context
The future of GLP-1 receptor agonists in weight management is a hot topic in peptide research. This article explores the latest developments, including next-generation compounds, oral formulations, and combination therapies, while providing context for peptide researchers and industry professionals.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
AlphaValue/Baader Europe Adjusts Bachem Price Target and Estimates Before H1 Results
AlphaValue/Baader Europe has revised its price target and financial estimates for Bachem, a peptide contract development and manufacturing organization (CDMO), ahead of the company's first-half 2026 results. The adjustments reflect updated expectations for the company's performance in the coming reporting period.
Cenna Biosciences Gets FDA Clearance for Phase 1 Trial of Alzheimer's Peptide 8M2D
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial for 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The announcement was made on June 17, 2026, marking a regulatory milestone for the experimental therapy.
GLP-1 RA Use Linked to Better Survival in Cancer Patients, Ontada Analysis Shows
An analysis by Ontada found that use of GLP-1 receptor agonists (GLP-1 RAs) was associated with improved survival outcomes in patients with cancer. The study, reported by AJMC, highlights a potential benefit of these drugs beyond their established role in diabetes and weight management.
Zepbound News: Why Setting Weight Loss Goals May Be Key to Success
Recent reports suggest that setting structured weight loss goals could be critical for success with Zepbound. This analysis explores the implications for peptide researchers and industry professionals, while contextualizing the drug within broader peptide science.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.
Copper Peptide Gains Traction Among Beauty Influencers
Copper peptide, an anti-aging compound, is experiencing a surge in popularity among wellness and beauty influencers, according to a report from Yahoo. The compound is being promoted for its potential skin-rejuvenating properties.
Lilly monthly obesity shot race with Peptron, Camurus heats up
Eli Lilly is pursuing a monthly obesity injection as South Korean biotech Peptron and Swedish Camurus compete to secure a licensing deal. The race highlights growing interest in less frequent dosing for weight loss treatments. Both companies are advancing their own long-acting formulations.
Cenna Biosciences Gets FDA Nod for Alzheimer's Peptide Trial
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The regulatory green light marks a key step toward testing the novel therapeutic in humans.
GLP-1 Drugs Linked to Reduced Crime-Related Behavior
A report from Inside Precision Medicine indicates that GLP-1 receptor agonists, commonly used for diabetes and weight loss, may be associated with a reduction in crime-linked behaviors. The findings suggest potential broader societal impacts of these medications beyond metabolic health.
Zepbound: Setting Weight Loss Goals May Boost Success, Study Suggests
A new article from Healthline reports that setting specific weight loss goals may be critical for success with the GLP-1 drug Zepbound. The piece highlights how structured goal-setting can improve outcomes for patients using the medication.
GLP-1 weight loss drugs linked to 30% lower breast cancer risk in women
A new study has found that GLP-1 weight loss drugs are associated with a 30% lower risk of breast cancer in women. The research adds to growing evidence that these medications may offer health benefits beyond weight management.
Ozempic and Wegovy linked to drop in violent behavior, study finds
A new study has found that the popular GLP-1 drugs Ozempic and Wegovy are linked to a decrease in violent behavior among users. The research, reported by NewsNation, adds to the growing body of evidence suggesting these medications may have broader effects beyond weight loss and blood sugar control.
PolyPeptide Group Faces Margin Adjustments Ahead of First Half Results
PolyPeptide Group is preparing for margin adjustments as it approaches the release of its first half 2026 financial results. The company, a contract development and manufacturing organization (CDMO) specializing in peptides, is reportedly making strategic pricing and cost adjustments to improve profitability. Investors are closely watching the upcoming results for signs of margin recovery.
EU Calmodulin-Binding Peptide Resins Market Analysis and Forecast 2026
IndexBox has published a new report analyzing the European Union market for calmodulin-binding peptide resins. The analysis covers market size, trends, and forecasts for the region. The report provides detailed insights into production, consumption, trade, and pricing dynamics across EU member states.
FDA Warns Telehealth Companies Over Compounded GLP-1 Drugs
The U.S. Food and Drug Administration has issued warnings to telehealth companies regarding the compounding of GLP-1 receptor agonists. The agency's actions target firms that may be producing or distributing unapproved versions of these popular diabetes and weight loss medications. The warnings underscore ongoing regulatory scrutiny of compounded semaglutide and tirzepatide products.
Zepbound News: Why Setting Weight Loss Goals May Be Key to Success
Recent reports suggest that setting structured weight loss goals may improve outcomes with Zepbound. This analysis explores the potential role of goal-setting in peptide-based weight management, offering context for researchers and industry professionals.
FDA Cracks Down on Telehealth Claims for Compounded Weight-Loss Drugs
The US FDA sent 25 warning letters to telehealth companies over unsubstantiated claims about compounded semaglutide and other weight-loss drugs. This action highlights regulatory scrutiny in the peptide and GLP-1 space, with implications for researchers and industry professionals.
US warns GLP-1 copycat makers over misleading claims
The United States has issued a warning to manufacturers of GLP-1 copycat drugs, cracking down on misleading claims about these products. The action targets makers who are reportedly marketing unauthorized versions of popular GLP-1 medications, which are used for diabetes and weight loss. The warning emphasizes that such claims could mislead consumers and violate regulations.
LG AI Research Develops AI for Oral Peptide Drug Discovery
LG AI Research is pursuing the discovery of oral peptide drugs using artificial intelligence. The initiative aims to design peptides that can be taken orally, overcoming a key challenge in peptide therapeutics. The project leverages LG's proprietary AI models for molecular design and optimization.
Showing 24 of 154 articles